Gastroesophageal Junction Adenocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Gastric Cancer (780)

Gastroesophageal Cancer (41)

Gastric Adenocarcinoma (40)

Gastric Cancer (780)

Gastroesophageal Cancer (41)

Gastric Adenocarcinoma (40)

›

HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	Sensitive: A1 - Approval Sensitive : A1	Sensitive: A1 - Approval Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1	disitamab vedotin Sensitive: A1 - Approval disitamab vedotin Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	tislelizumab-jsgr Sensitive: A1 - Approval tislelizumab-jsgr Sensitive : A1	tislelizumab-jsgr Sensitive: A1 - Approval tislelizumab-jsgr Sensitive : A1
HER-2 positive + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 positive + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 overexpression	Gastroesophageal Junction Adenocarcinoma	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1	trastuzumab-strf Sensitive: A1 - Approval trastuzumab-strf Sensitive : A1
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2	cisplatin + capecitabine Sensitive: A2 - Guideline cisplatin + capecitabine Sensitive : A2
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2

Gastroesophageal Junction Adenocarcinoma

Associations(185)

Associations
(185)